Rhenovia files patents for new treatment of Huntington’s disease based on its biosimulation platform
Rhenovia Pharma announced the filing of patents of a new method, a drug candidate, RHEDAR (TM) and a novel chemical series for treating Huntington’s disease (HD). RHEDAR is a significant step forward in the use of novel modes of action using Modeling and Simulation (M&S) for cost-effective drug discovery.
The new drug candidate aims to bring into equilibrium the dynamic biochemical and biophysical balances in one of the most affected brain regions in HD, the striatum. RHEDAR is available for out-licensing to the pharma and biotech industry, or for co-development with patient associations and foundations, governmental organizations or investment partners.
“Rhenovia continues to grow from strength to strength. Our latest achievement, RHEDAR, is proof of the relevance of our biosimulation technology that is showing real value as a highly efficient and cost-effective drug discovery method,” said Dr. Serge Bischoff, Rhenovia’s president and CEO. “To my knowledge, this is the first time that a drug candidate has been developed based on the discovery of a novel mode of action using M&S and we are excited by the opportunities it will offer customers and partners in the pharma and biotech industries.”
Biosimulation technology uses original datasets of experimental compounds, abandoned or approved drug candidates to uncover novel biological mechanisms affected by diseases. This enables researchers to re-profile and re-position molecules of interest into new therapeutic areas. M&S is also considered an invaluable instrument for the pharma industry to leverage past investment. The method could also allow biotechnology companies as well as patient associations and foundations to exploit the hundreds or thousands of potentially efficacious drug candidates sitting on shelves.
“By being able to discover new drugs with its innovative approach, Rhenovia has clearly demonstrated that biosimulation is a powerful approach for achieving many things. On top of optimizing drug discovery by validating targets, enhancing the efficacy of existing drug candidates and extending the life cycle of blockbusters via suitable, synergistic combinations or associations, it can also discover new drugs. That is outstanding,” said Prof. Michel Baudry, vice-president and CSO at Rhenovia.
Other news from the department research and development
